Details for Patent: 8,026,284
✉ Email this page to a colleague
Which drugs does patent 8,026,284 protect, and when does it expire?
Patent 8,026,284 protects PROCYSBI and is included in two NDAs.
Protection for PROCYSBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-nine patent family members in nineteen countries.
Summary for Patent: 8,026,284
Title: | Enterically coated cystamine, cysteamine and derivatives thereof |
Abstract: | The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects. |
Inventor(s): | Dohil; Ranjan (San Diego, CA), Schneider; Jerry (La Jolla, CA) |
Assignee: | The Regents of the University of California (Oakland, CA) |
Application Number: | 11/990,869 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,026,284 |
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 8,026,284
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Horizon | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Horizon | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Horizon | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-001 | Feb 14, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Horizon | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-002 | Feb 14, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,026,284
PCT Information | |||
PCT Filed | January 26, 2007 | PCT Application Number: | PCT/US2007/002325 |
PCT Publication Date: | August 09, 2007 | PCT Publication Number: | WO2007/089670 |
International Family Members for US Patent 8,026,284
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2007210005 | ⤷ Try a Trial | |||
Brazil | PI0707277 | ⤷ Try a Trial | |||
Canada | 2640531 | ⤷ Try a Trial | |||
Cyprus | 1113690 | ⤷ Try a Trial | |||
Cyprus | 1122943 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |